Literature DB >> 16900926

Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases.

Johan F Schoeman1, Graham Fieggen, Neil Seller, Marc Mendelson, Bennie Hartzenberg.   

Abstract

Paradoxical enlargement and development of new intracranial tuberculomas and tuberculous brain abscesses on adequate antituberculosis treatment are well recognized and supposedly cytokine mediated. These lesions are often unresponsive to conventional antituberculosis treatment, corticosteroids, and surgery. We therefore assessed the effect of adjunctive thalidomide, a tumor necrosis factor alpha-modulating drug, in intractable intracranial tuberculosis that did not respond to standard medical and surgical therapy. Four consecutive children (three children with bacteriologic proof and one child with clinical evidence of intracranial tuberculosis) were studied. Three patients each had a giant tuberculous abscess, and the fourth had chronic basal arachnoiditis with progressive loss of vision. Three of the four patients had relentless neurologic deterioration, and all showed disease progression on neuroimaging despite full medical and appropriate surgical treatment. Marked clinical and neuroradiologic improvement occurred after thalidomide was added to the antituberculosis treatment regimen of these four patients. Adjunctive thalidomide might have a role in the management of intractable intracranial tuberculosis and needs further investigation in this regard.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16900926     DOI: 10.1177/08830738060210040801

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  26 in total

1.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

2.  Pathogenesis and immune response in tuberculous meningitis.

Authors:  Bini Estela Isabel; Hernández Pando Rogelio
Journal:  Malays J Med Sci       Date:  2014-01

3.  Inflammatory bowel disease in Chinese children: A retrospective analysis of 49 cases.

Authors:  Ying Zhou; Ying Huang
Journal:  Exp Ther Med       Date:  2016-09-28       Impact factor: 2.447

4.  Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

Authors:  Steffen Hess; Toni Hospach; Robert Nossal; Günther Dannecker; Klaus Magdorf; Frank Uhlemann
Journal:  Eur J Pediatr       Date:  2011-05-31       Impact factor: 3.183

5.  Neurotuberculosis: Control of Steroid-Refractory Paradoxical Inflammatory Reaction With Ruxolitinib.

Authors:  Yingda L Xie; Fanny Ita-Nagy; Ray Y Chen; Maura M Manion; Irini Sereti; Luxin Pei; Steven M Holland
Journal:  Open Forum Infect Dis       Date:  2019-10-26       Impact factor: 3.835

Review 6.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

Review 7.  Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.

Authors:  Arundhati Maitra; Sadé Bates; Monisha Shaik; Dimitrios Evangelopoulos; Ibrahim Abubakar; Timothy D McHugh; Marc Lipman; Sanjib Bhakta
Journal:  Br Med Bull       Date:  2016-05-05       Impact factor: 4.291

Review 8.  The pathogenesis of tuberculous meningitis.

Authors:  Angharad Grace Davis; Ursula Karin Rohlwink; Alizé Proust; Anthony A Figaji; Robert J Wilkinson
Journal:  J Leukoc Biol       Date:  2019-01-15       Impact factor: 4.962

9.  Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma.

Authors:  Jae-Sook Ahn; Sung Yoon Rew; Deok-Hwan Yang; Sung-Hoon Jung; Seung-Ji Kang; Mi-Young Kim; Seung-Shin Lee; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Blood Res       Date:  2013-03-25

Review 10.  Management of patients with the immune reconstitution inflammatory syndrome.

Authors:  Suzaan Marais; Robert J Wilkinson; Dominique J Pepper; Graeme Meintjes
Journal:  Curr HIV/AIDS Rep       Date:  2009-08       Impact factor: 5.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.